Redeye updates its view on Xbrane following a Q2 report hinting at accelerating sales but also highl...
Solwers posted H1 revenue of EUR 39.9m, 2% above our expectations while profitability was lower due ...
Redeye updates on GiG following Q2-results which were overall close to our expectations and full foc...
Prospekteringsbolaget Bluelake Mineral (Bluelake) har tagit flera viktiga steg sedan föregående anal...
Northbaze announced yesterday the acquisition of Enter Sales & Distribution AB, a company with three...
Carlsquare Equity Research bedömer att start av influensaprojektet och flytten av labbverksamhet til...
Q2 challenging, same trends expected for Q3 Paper — better demand, more supply cuts, higher prices F...
Redeye concludes that Systemair’s Q1 numbers are quite in-line with what we anticipated.
Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue tha...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) är en modern spelkoncern beståe...
Redeye is pleased that Lifeclean is getting some traction on its efforts in the PFAS area.
Redeye comments on Scandion Oncology’s Q2 2024 report, shortly after the company announced that its ...
Solid sales growth (14% y-o-y) and positive FCF EBIT estimates down slightly on higher opex in Q2 7-...
CoinShares International (CS) redovisade en stark justerad EBITDA under Q2 24 på 26,6 miljoner pund ...
Redeye provides a more in-depth review of AcouSort’s Q2 report, which did not include any major surp...
Redeye comments on Verve Group’s Q2 2024 numbers, which align with preliminary figures.
EcoRub (”EcoRub” eller ”bolaget”) publicerade den 28 augusti 2024 bolagets delårsrapport för det and...
Supported by the latest troponin data generated from whole blood samples on the final commercial car...
Redeye comments on Maximum Entertainment’s Q2-results which saw softer topline than expected while a...
Etteplan lowered its guidance as the market conditions have remained weak.
